BioSpace News Archive

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the development and use of certain antibodies for the treatment of cancer and infectious diseases.

Mundipharma announced that it will embark on an ambitious series of studies both in vitro and in vivo to evaluate the effectiveness of its BETADINE® antiseptic products against the novel coronavirus which causes COVID-19 disease.

Zomedica Pharmaceuticals Corp., a veterinary diagnostic company, announced that it has completed the verification of TRUFORMA™, its point-of-care diagnostic biosensor platform, and the first assay, Canine total T4 thyroxine.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress..

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the first quarter 2020 after the close of trading on Thursday, April 30, 2020. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financi

Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints Ibrexafungerp was generally safe and well-tolerated Positive results consistent with previously reported VANISH-303 study support anticipated NDA submission for the treatment of vulvovaginal candidiasis (VVC) in the second half of 2020 Enrollment is ongoing in the CANDLE Phase 3 study of oral ibrexafungerp for the prevention of recurrent VVC, with supplemen

Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET. The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work

Company to Host Conference Call on Tuesday, May 5, 2020 at 1:30 p.m. PT / 4:30 p.m. ET

X-Biotix Therapeutics, Inc., announced the appointment of industry veteran, Michael W. Bonney to the company’s Board of Directors.

Cardiovascular Systems, Inc. to Webcast Fiscal 2020 Third-Quarter Earnings Conference Call Tuesday, May 5